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a b s t r a c t
Stenotrophomonas maltophilia is known for nosocomial habitat. Infective endocarditis due to
this organism is rare and challenging because of resistance to multiple broad-spectrum
antibiotic regimens. Early detection and appropriate antibiotic based on culture sensitivity
reports are the key to its management. We report the diagnosis, treatment, and outcome of
two cases of infective endocarditis caused by S. maltophilia.
# 2015 Cardiological Society of India. Published by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. BackgroundStenotrophomonas maltophilia (S. maltophilia) is a nonfermenta-
tive, gram-negative, aerobic bacillus that is widely distributed
in the nature. In a hospital setting, it has been found in water-
related sources and contaminated medical equipments.1–3
Although S. maltophilia is not highly virulent, its treatment is
challenging because of its resistance to multiple antibiotics.
Therefore, the relentless progression of patient's underlying
illness adds to higher causalities.4–7 Infective endocarditis due
to S. maltophilia is very rare. Only 41 cases have been reported
so far worldwide, most of which required surgical treatment.
In this report, we share our experience of two cases of infective
endocarditis managed by culture-sensitive antibiotics.* Corresponding author.
E-mail address: drsubhani03@gmail.com (S. Subhani).
http://dx.doi.org/10.1016/j.ihj.2015.07.048
0019-4832/# 2015 Cardiological Society of India. Published by Elsevier
(http://creativecommons.org/licenses/by-nc-nd/4.0/).2. Case report
2.1. Case 1
A 35-year-oldmanwas admitted to our hospital 3 months back
with history of fever with chills for ﬁve days. The patient had
undergone PBMV for severe rheumatic mitral stenosis 2 weeks
prior to this episode. No other predisposition was found. There
wasnohistory of dental proceduresor injections of intravenous
drugs. On physical examination, blood pressure was 110/
70 mmHg, pulse rate 85/min, and body temperature of 38 8C.
Cardiac examination revealed loudS1 andP2withgrade IIImid-
diastolic murmur at the apex. The remaining physical exami-
nation was unremarkable. There were no peripheral signs ofB.V. This is an open access article under the CC BY-NC-ND license
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Fig. 2 – Transesophagial echocardiography (TEE) image is
showing disappearance of vegetation after 2 weeks of
culture sensitive-based antibiotic regimen of case one.
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Fig. 3 – Transesophagial echocardiography (TEE) image is
showing mobile vegetation over prosthetic mitral leaflet of
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Hemoglobin was 12.8 gm/dl, white blood cell (WBC) was
18,900/L, erythrocyte sedimentation rate (ESR) was 52 mm in
ﬁrst hour, and urinalysis was normal. Renal parameters were
normal. Cardiomegaly was apparent in chest radiography.12
Electrocardiogram revealed a normal sinus rhythm. The
transthoracic echo demonstrated moderate mitral stenosis,
severe eccentric mitral regurgitation, which was not there
previously, and suspicious vegetation was present on mitral
valve. The transesophagial echocardiogram revealed freely
mobile sessile vegetation of size 5 mm 5 mm over both
anterior and posterior mitral leaﬂets (Fig. 1). The patient was
started with a regimen of ceftriaxone and gentamycin. S.
maltophilia was identiﬁed on blood culture and the antibiotics
were changed to co-trimoxazole and levoﬂoxacin as per culture
sensitivity report. After 1 week of antibiotics, patient became
afebrile, and repeat transesophagial echoafter 2weeks revealed
disappearance of vegetation (Fig. 2). Antibioticswere continued
for 6 weeks. He was discharged successfully.
2.2. Case 2
A 40-year-oldmanwas admitted for fever and chill for a period
of 2 months following mechanical valve replacement (27 mm
Carbo-Medics) of mitral valve for severe rheumatic mitral
stenosis. No other comorbidities were found. There was no
history of dental procedures or injections of intravenous
drugs. At presentation, he was drowsy, pale, and edematous
with raised jugular venous pulsation. Blood pressure was 90/
60 mmHg, pulse rate 120/min, and body temperature was
38 8C. Cardiac examination revealed soft S1, normal S2 with
metallic heart sound. There was no audible murmur. Chest
examination revealed bilateral basal crepitations. Glasgow
Coma Scale (GCS) at presentation was E3 M5 V4 with no focal
neurological deﬁcits. The rest of the physical examinationwas
unremarkable. Laboratory tests showed that Hbwas 7.6 gm/dl,
WBC 17,500/L, and ESR was 80 mm/hr. The renal parameters
were elevated with urea of 65 mg/dl and serum creatinine of[(Fig._1)TD$FIG]
Fig. 1 – Transesophagial echocardiography (TEE) image is
showing two mobile vegetations over anterior and
posterior mitral leaflet before treatment of case number
one.
case 2 who died in hospital.3.0 mg/dl. Arterial Blood Gas (ABG) revealed metabolic acido-
sis. Increased cardiothoracic ratio and features suggestive of
pulmonary edema were observed on chest radiography.
Electrocardiogram revealed sinus tachycardia. The transtho-
racic echo demonstrated large mobile vegetation of
2 cm  1.6 cm in size on prosthetic mitral valve (Fig. 3). There
was mild paravalvular leak with partial dehiscence, moderate
mitral regurgitation, moderate tricuspid valve regurgitation,
moderate pulmonary arterial hypertension, and moderate left
ventricular dysfunction. The patient was empirically started
on vancomycin and ceftriaxone. Initially, blood cultures grew
MRSA sensitive to only teicoplanin, gentamycin, and linezolid.
Fever continued with spikes. Supportive treatment was given
in the form of inotropic support, vasodilators, and peritoneal
dialysis for rapidly worsening renal dysfunction. By the time,
the repeat blood culture could identify the culprit bacteria to be
S. maltophilia, the patient died of septicemia and renal
dysfunction.
Table 1 – The brief summary of worldwide experience of Stenotrophomonas maltophilia infectious endocarditis.
Case Ref. Clinical proﬁle Management Complications Outcomes
Age/Sex Predisposing factors Valve
involved
MM Surgery
1 [9] 26/M Recent valve replacement
(<1 month)
PMV,
ASD patch
CHL, KAN, COL Yes Multiple septic emboli D
2 [9] 30/M Recent valve replacement
(<1 month)
PMV,
ASD patch
CHL No None C
3 [9] 65/F Cystoscopy, valve
replacement (7 months)
PMV CAR, GEN, KAN,
CHL, PEN, POL
Yes Persistent bacteremia C
4 [9] 35/M Recent valve replacement
(early), rheumatic carditis
PMV CAR, GEN, SXT No None C
5 [9] 38/M None PMV STR, PEN No Septic emboli, MI D
6 [9] 22/M IVDU PAV CAR, AMK, SXT Yes CHF, septic emboli C
7 [9] 31/F IVDU, dental treatment PAV CAR, KAN, SXT Yes Perivalvular abscess C
8 [9] 57/M IVDU, rheumatic carditis NAV, NMV POL, SXT No Septic emboli C
9 [9] 25/M None VSD repair GEN, CHL No NR D
10 [9] 33/M IVDU, aortic stenosis, atrial
ﬁstula
NAV, NTV TIC, MOX, SXT Yes CHF, myocardial abscess D
11 [9] NR CVC NTV NR NR NR D
12 [9] NR NR NAV NR NR NR D
13 [9] NR CVC NAV NR NR NR C
14 [9] 33/M IVDU, dental treatment PAV SXT, AMC, GEN Yes Perivalvular abscess C
15 [9] 56/M Recent valve replacement
(early)
PAV CAZ, GEN, SXT Yes Septic emboli D
16 [9] 32/M IVDU, subcutaneous reservoir NTV SXT No CHF D
17 [9] 28/M IVDU NAV CIP, GEN Yes Myocardial abscess C
18 [9] 60/F Ventriculo-atrial shunt NTV TIM, SXT No Lung abscess C
19 [9] 36/M Dental treatment (3 months) NAV TZP, GEN Yes CHF C
20 [9] 69/F Recent valve replacement
(3 months)
PMV, PAV CAZ, GEN, CIP, SXT Yes CHF, persistent bacteremia D
21 [10] 37/M Recent mitral valvuloplasty
(early)
PMV CAZ, AMK, CIP then
TIM, SXT, COL
Yes None C
22 [9] 58/F Recent valve replacement
(3 months)
PMV SXT Yes None C
23 [9] 62/M Recent valve replacement
(6 months)
PAV CIP, CHL No Aortic dissection C
24 [9] 40/M Recent valve replacement
(9 months)
PAV TIM, SXT No None C
25 [9] 44/M Rheumatic valvular disease PMV VAN, GEN No Recurrence with septic
emboli treated by TMP-SMZ
+ TOB and surgery
C
26 [11] 44/M IVDU, HIV, dental treatment,
rheumatic aortic and mitral
disease
NMV, NAV LVX, SXT No None C
27 [9] 56/F CVC NAV FEP, CIP, SXT No None C
28 [12] 65/F NR PAV NR NR CHF, paravalvular abscess NA
29 [7] 34/F Peripheral catheter PMV SXT, GEN No None C
30 [13] 38/M Recent valve replacement
(1 year)
PAV SXT, TIM Yes Subannular abscess C
31 [14] 28/M Recent valve replacement
(3 weeks)
PAV SXT, CAZ Yes None C
32 [15] – Pacemaker Pacemaker
pocket
– Yes None C
33–39 [8] 68–84 Recent valve replacement PAV CAZ Yes CNS complications in 4 3D
40 [16] 78/F None PMV SXT, CIP, TZP Yes Multiple cerebral infarction
and paravalvular abscess
D
41 [17] 23/F Autoimmunity related to SLE
42 Case 1 35/M Rheumatic heart disease Native
mitral valve
SXT, LVX No None C
43 Case 2 40/M Recent valve replacement
(4 months)
PMV VAN, GEN No Renal failure D
Out of 43 cases, 14 patients (33%) died out of various complications.
Abbreviations: AMC, ampicillin; AMK, amikacin; ASD, atrial septal defect; CAR, carbenicillin; CAZ, ceftazidime; CHF, congestive heart failure;
CHL, chloramphenicol; CIP, ciproﬂoxacin; COL, colistin; CVC, central venous catheter; FEP, cefepime; GEN, gentamicin; IVDU, intravenous drug
user; KAN, kanamycin; LVX, levoﬂoxacin; MI, myocardial infarction; MOX, moxalactam; NAV, natural aortic valve; NMV, natural mitral valve;
NR, not reported; PAV, prosthetic aortic valve; PEN, penicillin; PMV, prosthetic mitral valve; POL, polymyxin; PR, present report; STR,
streptomycin; SXT, trimethoprim-sulfamethoxazole; TIC, ticarcillin; TIM, ticarcillin-clavulanic acid; TOB, tobramycin; TZP, piperacillin-
tazobactam; VAN, vancomycin; VSD, ventricular septal defect. D, died; C, cure; MM, medical management; SLE, systemic lupus erythematous.
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maltophilia endocarditis of different outcomes. One patient
wasmanaged successfully with culture-guided early antibiotic
therapy, while other case succumbed before the arrival of
culture report.
S. maltophilia endocarditis is a rare disease. Only 41 cases
have been reported around the world before our observations
(Table 1). The clinical features vary from case to case. In-
hospital habitat is the reservoir. S. maltophilia endocarditis is
likely to develop under speciﬁc conditions, such as the use of
central venous lines, prior cardiac surgery, and intravenous
drug abuse.4–7 Thus, S. maltophilia from contaminated medical
equipment in hospitals may cause endocarditis when the skin
barrier is broken.2,6 In particular, prior valve replacement is
one of the predisposing factors that accounts for approxi-
mately 40–60% of the endocarditis cases.5–7
Treatment of endocarditis caused by S. maltophilia com-
prises appropriate antibiotic therapy and removal of indwell-
ing infected foreign material in the body. Because of limited
experience and resistance to multiple antibiotics, the treat-
ment is purely based on consensus and regional culture
sensitivity pattern. S. maltophilia is resistant to penicillin,
cephalosporin, and Carbapenems. Sulfamethoxazole-trimeth-
oprim is selected as the ﬁrst-line antibiotic, supported by
in vitro susceptibility.2,3 Since sulfamethoxazole-trimetho-
prim is bacteriostatic against the most isolates, it is used in
combination with other antibiotics for synergistic effect. The
difﬁculty in treating S. maltophilia endocarditis with antibiotic
therapy arises due to sulfamethoxazole-trimethoprim intol-
erance. Several reports have stated that combination therapy
with ﬂuoroquinolones, aminoglycosides, and 3rd or 4th
generation cephalosporin is effective.6,8 Discrepancies be-
tween the in vitro susceptibility data and clinical outcome
have been noted in the case of S. maltophilia infections.1,3 Both
morbidity andmortality rates are high in cases of endocarditis
caused by S. maltophilia. The overall incidence of mortality is
approximately 34.8% (15/43), as has been summarized from
case reports around theworld (Table 1). Complications such as
cerebral vascular disease, congestive heart failure, and organic
abscess are seen in 70–80% of patients5–7 because of antibiotic
resistance. Autoimmunity could be included as a novel
predisposing factor for S. maltophilia endocarditis, as reported
in case report by Carrillo-Córdova et al.17 Until now, to the best
of our knowledge, there is no published report of infective
endocarditis caused by S.maltophilia from Indian subcontinent.
4. ConclusionThe true epidemiological proﬁle of infective endocarditis due to
S. maltophilia is emerging. The treatment for this organism has
not been addressed in most recently updated infective
endocarditis guidelines. The very reason may be its rare
occurrence and paucity of experience. It is important to identify
thismicroorganism as quickly as possible, since S. maltophilia isresistant to ﬁrst line antibiotic therapy generally used in case of
nosocomial infections. This case report reemphasizes the
meticulous steps in the prevention of device-related infections
in operation theaters and cardiac catheterization laboratories.
These are the ﬁrst two case reports of infective endocarditis
caused by S. maltophilia from India.
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